Replimune Group, Inc. Faces Class Action Lawsuit; Investors Urged to Act Now

Upcoming Class Action Against Replimune Group, Inc.

On September 12, 2025, Levi & Korsinsky, LLP announced a class action lawsuit for investors of Replimune Group, Inc., identified by its NASDAQ symbol REPL. This action seeks to recover losses incurred by shareholders during a specified period, particularly due to allegations of securities fraud.

What Triggered the Lawsuit?

The class action is prompted by events that occurred between November 22, 2024, and July 21, 2025. Within this timeframe, various instances of alleged misleading statements regarding the company's IGNYTE trial and its prospects have emerged. According to the filed complaint, the defendants may have overstated the efficacy of their trial results, neglecting significant issues that were known or should have been acknowledged. This resulted in the FDA dismissing the IGNYTE trial due to its inadequacy and lack of control.

Important Details for Investors

If you're an investor in Replimune Group, it is essential to know about your rights concerning this lawsuit. The deadline to request appointment as a lead plaintiff is fast approaching on September 22, 2025. This process involves formally expressing your interest in leading the lawsuit and advocating for fellow investors.

Even if you don't wish to take on the role of lead plaintiff, you may still be eligible for any compensation awarded as part of the class settlement without incurring out-of-pocket costs. It is crucial to act within the stipulated timeframe.

For those interested in joining or learning more about the class action, Levi & Korsinsky has created a submission form, available through their website. Potentially affected investors can also reach out to attorney Joseph E. Levi directly via phone or email for further guidance.

No Cost to Participate

A defining element of this class action is that investors will not incur any direct costs to participate. Members of the class will not need to pay any fees or costs out of pocket. This makes it easier for affected shareholders to seek justice without the worry of financial barriers.

Levi & Korsinsky’s Track Record

Levi & Korsinsky, a law firm with over two decades of experience in securities litigation, has effectively garnered hundreds of millions for shareholders in past cases. They maintain a strong focus on complex securities fraud cases, making them a reliable choice for investors seeking legal representation.

With more than 70 dedicated team members, the firm is well-equipped to handle the intricate demands of a class action lawsuit. Their recognition within the securities litigation sector is underscored by being featured in ISS Securities Class Action Services' Top 50 Report consistently for several years.

Conclusion

For investors in Replimune Group, Inc., promptly reviewing the implications of this class action could be pivotal in securing financial restitution for losses. Whether you choose to participate as a lead plaintiff or simply seek compensation, timely action is essential. Be sure to reach out to Levi & Korsinsky for expert assistance and further details on how to navigate this legal process.

This potential class action highlights the importance of shareholder rights and the need for transparency in corporate communications, especially in the biotech and pharmaceutical sectors where timely and accurate information is crucial to investor confidence.